PAVmed (NASDAQ: PAVM) is one of 112 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its peers? We will compare PAVmed to related companies based on the strength of its risk, valuation, dividends, earnings, profitability, analyst recommendations and institutional ownership.
Insider & Institutional Ownership
6.7% of PAVmed shares are owned by institutional investors. Comparatively, 49.6% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 29.2% of PAVmed shares are owned by insiders. Comparatively, 15.3% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Volatility and Risk
PAVmed has a beta of -0.62, meaning that its stock price is 162% less volatile than the S&P 500. Comparatively, PAVmed’s peers have a beta of 0.82, meaning that their average stock price is 18% less volatile than the S&P 500.
This is a breakdown of current ratings and recommmendations for PAVmed and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
PAVmed presently has a consensus target price of $5.00, indicating a potential upside of 264.96%. As a group, “Surgical & medical instruments” companies have a potential upside of 2.80%. Given PAVmed’s stronger consensus rating and higher probable upside, equities analysts clearly believe PAVmed is more favorable than its peers.
This table compares PAVmed and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares PAVmed and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|PAVmed Competitors||$1.46 billion||$105.27 million||-192.66|
PAVmed’s peers have higher revenue and earnings than PAVmed. PAVmed is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
PAVmed Inc. operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York.
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.